The WACC of DaehanPharmaceutical (023910.KQ) is 7.7%.
| Range | Selected | |
| Cost of equity | 6.50% - 8.90% | 7.70% |
| Tax rate | 22.80% - 23.90% | 23.35% |
| Cost of debt | 7.00% - 7.00% | 7.00% |
| WACC | 6.5% - 8.9% | 7.7% |
| Category | Low | High |
| Long-term bond rate | 3.1% | 3.6% |
| Equity market risk premium | 5.8% | 6.8% |
| Adjusted beta | 0.59 | 0.7 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 6.50% | 8.90% |
| Tax rate | 22.80% | 23.90% |
| Debt/Equity ratio | 0 | 0 |
| Cost of debt | 7.00% | 7.00% |
| After-tax WACC | 6.5% | 8.9% |
| Selected WACC | 7.7% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for 023910.KQ:
cost_of_equity (7.70%) = risk_free_rate (3.35%) + equity_risk_premium (6.30%) * adjusted_beta (0.59) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.